Please assess the completion status of the following clinical trial:

Trial Title: Rifaximin in Patients With Gastroesophageal Variceal Bleeding

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 y.o. ≤age≤75 y.o.;~* Cirrhotic gastroesophageal variceal bleeding underwent endoscopic treatment (include esophageal varices ligation, endoscopic injection sclerosis and gastric N- butyl-cyanoacrylate injection).~Exclusion Criteria:~* age \<18 y.o. or age \> 75 y.o.;~* Never had the variceal bleeding episode before;~* Do not have endoscopic treatment;~* Combined with other malignant tumors (not exclude patients with hepatocellular carcinoma who don't need treatment at the moment);~* Known infection after endoscopic treatment (Fever, microbial cultures positive, et al.)~* Massive ascites or combined with other high-risk factors that require prophylaxis use of antibiotics.~* Acute variceal bleeding within 5 days.~* Refuse to participate

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Rifaximin Treatment Group (Type: EXPERIMENTAL): Rifaximin 400mg bid for 2 months,
- Control Group (Type: NO_INTERVENTION): Receive routine endoscopic treatment without having rifaximin for 2 months

Based on this trial design, predict the completion outcome and termination type (if applicable).